Sam Brusco, Associate Editor06.16.22
Peripheral vascular, neurovascular, and cardiology firm Artio Medical has closed $28 million in oversubscribed Series A2 and A3 financing. This brings the company’s total raised to $74 million.
The funds will be leveraged to support U.S. commercialization for the recently FDA-cleared Solus Gold embolization device and accelerate product development, including an expansion of engineering and manufacturing capabilities.
Artio is currently developing ten peripheral vascular products, including Solus Gold and Solus Flex embolization devices for peripheral vessel occlusion and the Amplifi vein dilation system to prepare hemodialysis patients for successful arteriovenous fistula vascular access site creation.
The company is also currently developing four products for the neurovascular market, including the Endura embolization system, a detachable balloon and coils for saccular brain aneurysm treatment.
"We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio," Joseph McConnell, Artio’s VP of finance and business operations told the press. "We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people. This new capital will help Artio expand our team and scale our operations to deliver on that mission."
The funds will be leveraged to support U.S. commercialization for the recently FDA-cleared Solus Gold embolization device and accelerate product development, including an expansion of engineering and manufacturing capabilities.
Artio is currently developing ten peripheral vascular products, including Solus Gold and Solus Flex embolization devices for peripheral vessel occlusion and the Amplifi vein dilation system to prepare hemodialysis patients for successful arteriovenous fistula vascular access site creation.
The company is also currently developing four products for the neurovascular market, including the Endura embolization system, a detachable balloon and coils for saccular brain aneurysm treatment.
"We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio," Joseph McConnell, Artio’s VP of finance and business operations told the press. "We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people. This new capital will help Artio expand our team and scale our operations to deliver on that mission."